Mirvat Alasnag, MD, spoke to Cardiovascular Business about CCTA's growing influence in cardiology. 

The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.

This is a Class I recall, which means the FDA believes these devices could cause a serious injury or death.

Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.

President Trump, 79, says he is still in excellent health. He also has no intention of cutting down on the high dose of aspirin he takes each day.

This news follows similar announcements from Humana, Cigna and UnitedHealthcare; a majority of insured Americans can now be treated with these technologies and have the procedure covered by their provider. 

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.

ASE President David Wiener detailed some of the many ways imaging societies need to adapt now that so many imagers are specializing in multiple modalities. It may be time to change how annual conferences are scheduled, for example, so that the costs of travel are easier to manage.

RSNA is looking for a replacement for Suhny Abbara, MD, who is now the editor-in-chief of its flagship journal.